Lycopene-whey complex (bioavailable lycopene) and risk of atherosclerotic plaques Scientific substantiation of a health claim related to Lycopene-whey complex (bioavailable lycopene) and reduction of the risk of atherosclerotic plaques pursuant to Article 14 of Regulation (EC) No 1924/2006 [1]
Meta data
Keywords
lycopene, lipoprotein oxidisability, atherosclerotic plaques, atherosclerosis, health claim
Question Number
EFSA-Q-2008-703
Panel members at the time of adoption
Jean-Louis Bresson, Albert Flynn, Marina Heinonen, Karin Hulshof, Hannu Korhonen, Pagona
Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Hildegard
Przyrembel, Seppo Salminen, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Henk van den
Berg, Hendrik van Loveren and Hans Verhagen.
Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Hildegard
Przyrembel, Seppo Salminen, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Henk van den
Berg, Hendrik van Loveren and Hans Verhagen.
Abstract
No abstract available
© European Food Safety Authority, 2009